Article:Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies (5080363)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies and the publication date was 2016-12-01. The initial author is Maria Fleseriu.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Pituitary

Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies

  • Maria Fleseriu
  • Frederic Castinetti

Publication date (epub): 9/2016

Publication date (pmc-release): 9/2016

Publication date (ppub): /2016



Endogenous Cushing’s syndrome (CS) is a rare disease that results from exposure to high levels of cortisol; Cushing’s disease (CD) is the most frequent form of CS. Patients with CS suffer from a variety of comorbidities that increase the risk of mortality. Surgical resection of the disease-causing lesion is generally the first-line treatment of CS. However, some patients may not be eligible for surgery due to comorbidities, and approximately 25 % of patients, especially those with CD, have recurrent disease. For these patients, adrenal steroidogenesis inhibitors may control cortisol elevation and subsequent symptomatology. CS is rare overall, and clinical studies of adrenal steroidogenesis inhibitors are often small and, in many cases, data are limited regarding the efficacy and safety of these treatments. Our aim was to better characterize the profiles of efficacy and safety of currently available adrenal steroidogenesis inhibitors, including drugs currently in development.


We performed a systematic review of the literature regarding adrenal steroidogenesis inhibitors, focusing on novel drugs.


Currently available adrenal steroidogenesis inhibitors, including ketoconazole, metyrapone, etomidate, and mitotane, have variable efficacy and significant side effects, and none are approved by the US Food and Drug Administration for CS. Therefore, there is a clear need for novel, prospectively studied agents that have greater efficacy and a low rate of adverse side effects. Efficacy and safety data of current and emerging adrenal steroidogenesis inhibitors, including osilodrostat (LCI699) and levoketoconazole (COR-003), show promising results that will have to be confirmed in larger-scale phase 3 studies (currently ongoing).


The management of CS, and particularly CD, remains challenging. Adrenal steroidogenesis inhibitors can be of major interest to control the hypercortisolism at any time point, either before or after surgery, as discussed in this review.



Cushing’s syndrome (CS) is a potentially fatal disease associated with chronic hypercortisolemia [[1]]. Endogenous CS is rare, with an annual estimated incidence of approximately 0.7–2.4 cases per million people [[1]]. Patients with CS have a mortality risk that is approximately 3.5–5 times higher than the general population if not appropriately treated [[2]]. The increased mortality with CS is, in part, related to an increased risk of cardiovascular disease and coagulation disorders [[3][5]]. The risk of myocardial infarction is approximately 4.5 times higher, and the risk of venous thromboembolism is approximately 20.6 times higher in patients with CS compared with the general population [[2]]. Elevated cortisol levels in patients with CS also result in a range of comorbidities, including cardiovascular (e.g., venous thrombosis, hypertension), dermatological (e.g., plethora, ecchymoses), metabolic (e.g., weight gain, abnormal glucose tolerance), reproductive (e.g., decreased libido, menstrual changes), neuropsychiatric (e.g., lethargy, depression), and musculoskeletal (e.g., muscle weakness) symptoms [[1]].

Treatment options that directly address the hypercortisolemia include surgery (pituitary, adrenal, or ectopic tumor resection), medical treatment, and/or radiotherapy [[6], [7]]. Each option has its drawbacks; for instance, radiation techniques become fully effective only after a prolonged period of time (3–5 years) and medical treatment, as a bridge is necessary. Focusing more specifically on Cushing’s disease (CD), the most frequent etiology of CS, the 2015 Endocrine Society Clinical Practice Guideline recommends surgical resection of the pituitary lesion as a first line of treatment, unless surgery is contraindicated or unlikely to successfully reduce excess cortisol levels [[6]]. For patients for whom disease was not controlled by initial surgery, or for patients with severe, life-threatening disease, bilateral adrenalectomy is also an option [[6]]. However, as a result of the adrenal insufficiency (AI) induced by bilateral adrenalectomy, patients undergoing the procedure will require hydrocortisone replacement and have an increased risk of adrenal crises during their lifetime [[8]].

Medical treatment is recommended in patients who are not surgical candidates, or for whom surgery has failed, and in patients awaiting the effects of radiation therapy/radiosurgery [[6]].

There are three specific targets for medical therapy in CD, the corticotroph tumor, adrenal steroidogenesis inhibitors, and glucocorticoid receptor blockers.

Steroidogenesis inhibitors are recommended by the Endocrine Society as second-line treatment after adenomectomy in CD, depending on clinical circumstances; as first-line treatment for patients with ectopic adrenocorticotropic hormone (ACTH) secretion when a tumor is not detected; or as an adjunct treatment for patients with adrenocortical carcinoma [[6]].

Corticotropin (ACTH) stimulates steroidogenesis by the adrenal glands [[9]]. Through a variety of enzymatic reactions, cholesterol, the common steroid precursor, is converted to aldosterone, cortisol, or androstenedione (Fig. 1). Adrenal steroidogenesis inhibitors, which act by blocking various steps in the steroid biosynthesis pathway resulting in reduced production of cortisol and other steroids, are a cornerstone of medical treatment of CS [[10]]. This review summarizes the key features of different adrenal steroidogenesis inhibitors for the treatment of CS, with particular emphasis on steroidogenesis inhibitors currently in clinical development. Mechanisms of action, efficacy, and safety of the adrenal steroidogenesis inhibitors are discussed in detail below and summarized in Table 1.Fig. 1

Effects of adrenal steroidogenesis inhibitors on the cortisol synthesis pathway [[9]]. The enzymatic pathways in cortisol synthesis are represented schematically. Inhibitors are depicted in purple boxes and may inhibit multiple steps in the pathway. aAt high doses. CYP, cytochrome P450

Table 1

Mechanisms of action of steroidogenesis inhibitors [[21]]

Mechanism of action Efficacy (%) Common side effects
Ketoconazole Inhibitor of CYP17A1, CYP11A1, and CYP11B1 53–88 Liver enzyme increase
Gastrointestinal AEs
Interactions with multiple drugs
Not approved for use during pregnancy
Metyrapone Inhibitor of CYP11B1, CYP11B2, and CYP17A1 75 Hypokalemia
Gastrointestinal AEs
Not approved for use during pregnancy
Etomidate Inhibitor of CYP11B1, CYP17A1, and CYP11A1 NR Hypnosis
Not approved for use during pregnancy
Mitotane Inhibitor of CYP11A1, CYP11B1, and CYP11B2 ~70 Gastrointestinal AEs
Neurological side effects
Teratogen (not approved for use during pregnancy)
Osilodrostat (LCI699) Inhibitor of CYP11B2 and CYP11B1 at higher doses 78–92 Nausea
Not approved for use during pregnancy
Levoketoconazole (COR-003) Inhibitor of CYP17A1, CYP11A1, CYP11B1, and CYP21A2 NR Headachea
Mild liver enzyme increasea
Not approved for use during pregnancy

CYP, cytochrome P450; AE, adverse event; NR, not reported. All of these drugs can induce adrenal insufficiency

aIn patients with diabetes mellitus

Adrenal steroidogenesis inhibitors currently in clinical use


Ketoconazole, a synthetic imidazole derivative, is an antifungal that, at higher doses (400–1200 mg), reduces adrenal steroid production [[11]]. However, due to liver toxicity, the approved use of ketoconazole in the United States (US) is restricted to the treatment of serious fungal infections with no other viable treatment options [[7], [12]]. Ketoconazole is approved for the treatment of CS in the European Union [[13]]. While not approved for the treatment of CS by the US Food and Drug Administration (FDA), ketoconazole is one of the most commonly used steroidogenesis inhibitors for off-label treatment of CS [[11]].

Ketoconazole inhibits key cytochrome P450 (CYP) enzymes involved in multiple steps of steroidogenesis in the adrenal cortex, including CYP17A1, CYP11A1, CYP11B1, and CYP11B2 [[10], [14], [15]]. Ketoconazole is a 50/50 racemic mixture of 2S,4R and 2R,4S enantiomers [[16]], and these enantiomers exhibit differences in inhibitory potency for the enzymes involved in steroidogenesis [[17][19]]. Ketoconazole has also been reported to directly inhibit ACTH secretion [[20]], although these findings have not been confirmed [[21]].

In patients with CS, ketoconazole treatment has been associated with significant decreases in urinary free cortisol (UFC) and urinary levels of cortisol and androgen metabolites [[22]]. A retrospective study of 200 patients receiving single-agent ketoconazole reported that 50 % of the patients had normal UFC at the end of the study, while 26 % of “uncontrolled” patients had a ≥50 % decrease in UFC; concurrent improvements in hypertension, diabetes, and hypokalemia were also observed [[23]]. Escape from ketoconazole-mediated control occurred in some patients (7 %) [[8]]. However, interestingly, 50 % of the patients treated for more than 24 months (mean = 108 months) remained controlled with a stable dose of ketoconazole [[23]].

Elevations in liver enzymes occurred in approximately 15 % of patients treated with ketoconazole [[23], [24]]. Liver enzyme levels returned to normal within 1–4 weeks after lowering the dose or discontinuing treatment, and severe drug-induced liver injury was rare [[25]]. In this retrospective analysis, no fatal hepatitis was observed; however, a dramatic (~40-fold) increase in liver enzymes was observed in one patient who was consuming concomitant alcohol and high-dose acetaminophen [[23]]. Similarly, in retrospective chart review, elevation of liver enzymes and severe acute liver injury were rarely observed with ketoconazole treatment [[26]].

Concomitant use of drugs with known hepatotoxic effects should be avoided, and acid-lowering drugs should be used with caution, as they decrease the efficacy of ketoconazole [[24]]. Adrenal insufficiency is rare, except when the treatment is given as a block-and-replace strategy (a regimen in which cortisol production is completely inhibited by steroidogenesis inhibitors and glucocorticoids are administered to fulfill physiologic needs) [[23]]. Ketoconazole may also affect gonadal testosterone synthesis, resulting in decreased androgen levels and subsequent hypogonadism and gynecomastia in male patients; therefore, it is generally used as a second-line medical therapy in men (patients in whom metyrapone might be more appropriate, from this point of view) [[11], [25]].


Metyrapone is FDA approved for the diagnosis of AI in the US [[27]] and is used clinically, off label, for the treatment of CS [[10]]. In the European Union, metyrapone is approved for the treatment of CS [[13]]. Metyrapone exhibits potent, relatively selective inhibition of CYP11B1, but also inhibits the activity of CYP11B2 [[28]]. Significant reductions in urinary secretion of cortisol and aldosterone have been observed with metyrapone treatment [[29]]. In a retrospective study of 164 patients with CS who received metyrapone monotherapy, 43–76 % of patients achieved control of cortisol levels (defined by prespecified values of mean serum cortisol day-curve, 24-hour UFC, and 09.00 h cortisol) [[30]]. No escape was reported, and 83 % of the patients treated for more than 12 months (mean = 22 months) were controlled on a stable dose of metyrapone [[30]].

Metyrapone has been associated with gastrointestinal adverse events and hypoadrenalism [[6], [30]]. Despite the accumulation of adrenogenic and mineralocorticoid precursors associated with metyrapone treatment, incidence of metyrapone-related hirsutism, acne, and edema were rare, albeit not prospectively studied, and hypokalemia was reported but manageable with replacement [[30]]. Of note, some patients were initially treated with antialdosterone drugs, which might have led to an underestimation of worsening of hypokalemia and hypertension. Although no clear recommendation has been made on this specific point, metyrapone is probably a better choice for a second-line medical treatment in females for whom a long-term treatment is necessary because of hyperandrogenism [[6]].


Etomidate, an imidazole derivative, is used for the induction of anesthesia and is also a potent and dose-dependent inhibitor of CYP11B1, CYP17A1, and CYP11A1 [[6], [21], [31], [32]]. Etomidate can be administered intravenously and is often used for seriously ill patients with severe hypercortisolemia who cannot take oral medication [[6], [21]]. However, only a few cases of its use have been reported in the literature.

Earlier studies demonstrated that inhibition of cortisol was rapidly achieved with low-dose (2.5 mg/h) etomidate in patients with hypercortisolism and was distinct from the sedative effects of the drug [[33]]. In patients with CS, etomidate treatment resulted in significant suppression of serum cortisol levels within 11 h of infusion [[34]]. In an emergency setting, patients with CS who received etomidate at a dose of 0.1 mg/kg per hour exhibited rapid and prolonged suppression of serum cortisol levels [[34]]. The most common side effects associated with etomidate were hypnotic effect, reduced blood pressure, myoclonus, dystonia, nausea, and vomiting [[31], [33]]. Adrenal insufficiency has also been reported, which may require glucocorticoid replacement [[31]], thus a block-and-replace protocol is used in most cases. Etomidate is unstable in water, and is often administered in a formulation containing propylene glycol, which may increase the incidence of hemolysis and nephrotoxicity [[33]].


Mitotane, a synthetic derivative of the pesticide dichlorodiphenyltrichloroethane, is indicated for the treatment of adrenocortical carcinoma, but in rare cases may be used for the treatment of hypercortisolemia [[10], [35]]. Mitotane inhibits CYP11A1, CYP11B1, CYP11B2, and 5α-reductase [[7], [10]]. In patients with CS, mitotane treatment has been associated with significant reductions in cortisol and androgen levels [[36]]. In the largest study (76 patients) reported to date on the use of mitotane in CD, control of cortisol hypersecretion was observed in 72 % of the patients after a median time of 6.7 months; the mitotane level necessary to obtain control was lower than the level recommended for the treatment of adrenal carcinoma (8.5 vs 14 µg/L, respectively). Interestingly, 75 % of the patients needed to be treated with hydrocortisone in parallel, probably due to adrenal atrophy, but this effect was transient in the majority of the patients, as withdrawal of the drug led to recurrence in 71 % of them [[37]]. Results were similar in patients treated for ectopic ACTH secretion; 21/23 patients (91 %) achieved normal UFC levels after a mean time of 4.5 months [[38]].

Mitotane is associated with a number of potential side effects, including hypercholesterolemia, anorexia, gastrointestinal symptoms, decreased memory and other neurological side effects, and abnormal liver function [[31], [38]]; these side effects lead to discontinuation of treatment in approximately a quarter of patients and require close monitoring of plasma mitotane levels [[6]]. A recent study of premenopausal women demonstrated a high incidence of menstrual disorders and ovarian macrocysts in women receiving mitotane, which may be related to elevated levels of luteinizing hormone, follicle-stimulating hormone, and estrogen as a consequence of mitotane alleviating the negative feedback normally exerted by the ovaries on the production of those hormones [[39]].

Adrenal steroidogenesis inhibitors in clinical development

Osilodrostat (LCI699)

Osilodrostat is a potent and relatively selective inhibitor of CYP11B2 that also inhibits CYP11B1 at higher doses [[40]]. In comparison to metyrapone, which also inhibits CYP11B1, osilodrostat is a more potent inhibitor of CYP11B1 (IC50 2.5 vs 7.5 nM) and has a longer half-life (4–5 vs 2 h) [[41]]. Osilodrostat was initially developed as a possible treatment option for hypertension, cardiac failure, and renal disease [[10]]. In studies in patients with hypertension, significant and dose-dependent decreases in urine and plasma levels of aldosterone and a blunting of the cortisol response to synthetic ACTH were observed [[10]].

In a 10-week, proof-of-concept study in patients with CD (n = 12) who had previously undergone pituitary surgery and had UFC greater than 1.5 times the upper limit of normal (ULN), 92 % of patients achieved normalization of UFC within 10 weeks of initiating osilodrostat treatment, with all patients achieving ≥50 % decreases in UFC levels from baseline [[42]]. After treatment discontinuation, UFC levels rose above the ULN [[42]]. In a longer term, 22-week, phase 2 study of osilodrostat in patients with CD with UFC levels above the ULN, normalization of cortisol levels was achieved in 84 % of patients by week 10 and 79 % by the end of the study [[41]]. In both studies, patients achieved normal UFC within a month of starting treatment [[41], [42]]. Plasma levels of cortisol and aldosterone were decreased in both studies, while levels of their precursors, 11-deoxycortisol and 11-deoxycorticosterone, increased [[41], [42]]. Although blood pressure decreased from baseline in the proof-of-concept study, data from the phase 2 study showed no changes in blood pressure [[41], [42]].

In patients with CD, osilodrostat is also associated with an increase in ACTH (3- to 4-fold), which, due to the subsequent increase in 11-deoxycorticosterone, may be associated with the development of certain side effects (worsening of hypokalemia, increased blood pressure levels) [[10]]. These side effects were not specifically reported in the studies previously described. Adrenal insufficiency was observed in approximately 32 % of patients in the phase 2 study [[41]]. The most common adverse events in both studies were gastrointestinal adverse events (e.g., nausea, diarrhea); adverse events associated with adrenal insufficiency (i.e., fatigue, dizziness, nausea, muscle spasms, hypotension, and syncope) led to dose reductions of osilodrostat [[41], [42]]. In both studies, increased levels of testosterone were observed in female patients [[41], [42]], and in the phase 2 study, symptoms of hirsutism occurred in a third of the female patients who completed the study [[41]].

A phase 3, double-blind, randomized withdrawal study ( identifier NCT02180217) of osilodrostat in patients with persistent, recurrent CD or untreated CD who are not candidates for surgery is ongoing (estimated enrollment = 132) [[43]]. Patients receive osilodrostat during a 12-week, open-label, dose-titration period (weeks 1–12), followed by a 12-week, open-label, stable treatment period (weeks 13–24); then patients are randomized to receive osilodrostat or a placebo during an 8-week double-blind period (weeks 26–34), and, finally, all patients receive open-label osilodrostat from weeks 35 to 48. The primary endpoint is the proportion of patients with normal mean UFC values per treatment group at 34 weeks.

Levoketoconazole (COR-003)

Levoketoconazole is the 2S,4R enantiomer of ketoconazole, purified from racemic ketoconazole [[44]]. In early in vitro analyses, levoketoconazole was shown to be a more potent inhibitor than the 2R,4S enantiomer of several enzymes in the steroidogenic pathway, including CYP11B1, a key enzyme in the final step of adrenal cortisol synthesis; levoketoconazole had a half maximal inhibitory concentration for CYP11B1 that was approximately 4 times lower than the 2R,4S enantiomer [[17][19]]. As an azole antifungal, levoketoconazole was screened as an inhibitor of a critical enzyme for fungal survival, CYP51A1, which also happens to be a key enzyme in cholesterol synthesis. Levoketoconazole was shown to be a more potent inhibitor of CYP51A1 than the 2R,4S enantiomer [[19]]. Results of more recent analyses of the effects of racemic ketoconazole, levoketoconazole, and 2R,4S-ketoconazole on steroidogenic CYP enzymes support those of early in vitro studies [[45]]. In those analyses, levoketoconazole showed more potent inhibition of CYP17A1, CYP21A2, and CYP11B1 than either racemic ketoconazole or 2R,4S-ketoconazole [[45]]. Thus, a lower dose of levoketoconazole may potentially be used to achieve the same clinical effects as racemic ketoconazole; however, controlled clinical trials of different doses of levoketoconazole compared with racemic ketoconazole are needed to support these findings. In preclinical studies in rats, levoketoconazole had a greater potency for decreasing corticosterone (the main glucocorticoid in rats [[46]]) and testosterone levels than the 2R,4S enantiomer or racemic ketoconazole [[45]]. Levoketoconazole-mediated decreases in corticosterone were dose-dependent. Levoketoconazole treatment has not yet been evaluated in patients with CS; however, clinical results in healthy subjects and patients with type 2 diabetes support preclinical results showing suppression of corticosterone by levoketoconazole. In an analysis of cortisol levels over time in healthy subjects, the mean area under the curve (AUC) for cortisol was lower following administration of both levoketoconazole and ketoconazole compared with placebo. In a study in patients with type 2 diabetes, nonsignificant mean reductions in 12-hour overnight plasma cortisol AUC were observed with both ketoconazole and levoketoconazole after 14 days of dosing [[47]]. Interestingly, no dose-dependent trend in the percentage change in testosterone was found with levoketoconazole administration [[47]]. Finally, significant decreases in low-density lipoprotein cholesterol levels were observed in diabetic patients treated with levoketoconazole [[47]]. Levoketoconazole treatment also resulted in nonsignificant lower serum cholesterol levels in rats than the 2R,4S enantiomer or racemic ketoconazole. This may be of particular clinical relevance for patients with CS who have a substantially increased risk of cardiovascular events [[2]].

In patients with type 2 diabetes, headache and nausea were the most commonly reported adverse events [[47]]. Although levoketoconazole treatment has not yet been evaluated in patients with CS, levoketoconazole may have a more favorable safety profile than racemic ketoconazole, which has been associated with clinically relevant drug–drug interactions and hepatotoxicity. The pharmacokinetic profiles of levoketoconazole and the 2R,4S enantiomer suggest preferred extraction of the 2R,4S enantiomer by the liver, which may indicate a lower risk of hepatotoxicity with levoketoconazole [[45]]. In addition, levoketoconazole shows less potent inhibition of CYP7A1, a rate-limiting enzyme in bile acid synthesis, than the 2R,4S enantiomer [[47]]. Nevertheless, there has been some clinical evidence of alterations in liver function enzymes with levoketoconazole treatment [[47], [48]]; further studies will be needed to clarify whether decreased hepatotoxicity is observed with levoketoconazole in patients with CS. A single-arm, open-label, dose-titration study evaluating levoketoconazole in patients with persistent or recurrent CS, or newly diagnosed patients who are not candidates for surgery, is ongoing ( identifier NCT01838551) [[44]]. The study has a variable dose-titration phase, a 6-month maintenance phase in which patients receive levoketoconazole at the therapeutic dose, and a 6-month extended evaluation phase. The primary endpoint is the rate of normalized 24-hour UFC at 6 months of maintenance without dose increase; safety issues are closely monitored in this study.

Clinical considerations for treatment with adrenal steroidogenesis inhibitors in CS

Drug interactions

Most adrenal steroidogenesis inhibitors have the potential for drug interactions with drugs metabolized by CYP enzymes (Table 2). Both mitotane and ketoconazole are strong inhibitors of CYP3A4 and may enhance the activity of drugs metabolized by CYP3A4, including oral anticoagulants, statins, cyclosporine, and tacrolimus [[49][51]]. The inhibitory effects of mitotane treatment on CYP3A4 are long lasting and have been observed several months after therapy is discontinued [[51]]. Levoketoconazole has similar effects to those of racemic ketoconazole on the CYP enzymes most relevant to drug metabolism [[45]]. Like ketoconazole, levoketoconazole has the potential for drug interactions with drugs metabolized via CYP3A4 (e.g., felodipine and atorvastatin) [[45]]. In drug interaction studies, exposure of felodipine was increased 10-fold with coadministration of levoketoconazole, while exposure to atorvastatin was increased by ~30 % when coadministered with levoketoconazole (compared with a ~50 % increase with coadministration of racemic ketoconazole). In vitro data have also indicated that ketoconazole inhibits the cardiac potassium channel, hERG, which may result in prolongation of QT interval; thus, ketoconazole should be used with caution when used in combination with agents that also prolong QT interval or are metabolized by CYP3A4 [[52]]. In studies of healthy subjects, ketoconazole significantly increased QT interval [[53], [54]]. A trend toward prolongation of QT interval was also reported in a study of levoketoconazole in healthy subjects [[45]]. While it is likely that the effect of levoketoconazole on QT interval will be similar to that of ketoconazole, additional studies are needed. Mifepristone, a glucocorticoid receptor antagonist, is also metabolized by CYP3A; thus, drugs that inhibit CYP3A, such as ketoconazole and levoketoconazole, may increase plasma mifepristone concentrations [[55]]. Coadministration of these drugs is rare; however, it is important to ensure an adequate wash-out when switching from one therapy to another.Table 2

Drug–drug interactions with adrenal steroidogenesis inhibitors

Medical intervention Interacts with Potential for adverse event
Ketoconazole [[24], [54], [69]] CYP3A4 Drug–drug interactions with oral anticoagulants, statins, cyclosporine, and tacrolimus
hERG Possible QT prolongation
Use acid-lowering and hepatotoxic drugs with caution
Metyrapone [[68]] UGT1 Drug–drug interactions occur frequently
Acetaminophen toxicity
Etomidate [[70][73]] CYP11B1 Etomidate should be given carefully with calcium channel blockers, opioids, and benzodiazepines
Mitotane [[35]] CYP3A4 Drug–drug interactions with oral anticoagulants, statins, cyclosporine, and tacrolimus
Hydrocortisone dose increased
Osilodrostat (LCI699) [[21], [60], [74]] CYP1A2 and CYP2C19 (moderate inhibition)CYP2D6 and CYP3A4 (weakly inhibited) Drug–drug interactionsPossible QT prolongation
Levoketoconazole (COR-003) [[21]] CYP3A4, CYP3A5hERG Drug–drug interactions with oral anticoagulants, statins, cyclosporine, and tacrolimus
QT prolongation

CYP, cytochrome P450; hERG, human ether-a-go–go–related gene; UGT1, UDP-glucuronosyltransferase 1 family; NR, not reported

Combination therapy

Steroidogenic inhibitors are typically administered as monotherapy [[6]]. Combination therapy may be necessary in patients who do not respond to monotherapy or who experience dose-limiting side effects [[10]]. In patients with severe CS, combining more than two adrenal steroidogenesis inhibitors has also been shown to be effective. Combination therapy with ketoconazole and cabergoline normalized UFC in 79 % of patients with CD; however, based on late-night salivary cortisol levels, subclinical hypercortisolism persisted in patients treated with this combination [[56]]. In a study of 17 patients with CD, treatment with a regimen of pasireotide, cabergoline, and ketoconazole normalized UFC levels in 88 % of patients by day 80; reductions in UFC levels of up to 67 % were observed in patients with mild (1 to <2 times ULN) or severe (4–6 times ULN) CD [[57]]. Combination therapy with ketoconazole and metyrapone is relatively common, but is generally only considered for patients with more severe disease or for those who have failed to respond to monotherapy with either agent [[10], [30]]. Due to the relatively slow onset of action of mitotane, combination therapy with a rapid-onset steroidogenesis inhibitor may be used during the first several months of treatment [[10]]. In patients with severe hypercortisolism (UFC >5 times ULN) related to ectopic ACTH syndrome or adrenal carcinoma, the combination of metyrapone and ketoconazole (and in some patients, subsequent mitotane) resulted in normal UFC values in 73 % of patients (n = 22) and a concomitant improvement of clinical symptoms, including hypokalemia, hypertension, and diabetes [[58]]. Similarly, in a study of 11 patients with severe hypercortisolism and significant comorbidities that precluded surgical intervention, who were administered metyrapone and ketoconazole followed by mitotane maintenance therapy, UFC was normalized in all patients receiving combination therapy and remained below the ULN on maintenance therapy; all patients were able to undergo surgery 5–22 months after beginning combination therapy [[59]].

In mice, the combination of osilodrostat and pasireotide was similar to the toxicity of either agent alone and appeared to ameliorate the cellular hypertrophy associated with osilodrostat therapy and the decrease in liver weight following pasireotide therapy [[60]]. Additional studies are needed in patients with CD to confirm these results. Combination therapy with levoketoconazole has not yet been evaluated in patients with CS; however, based on the in vitro data, it is hypothesized that the greater potency of levoketoconazole for cortisol suppression relative to ketoconazole, along with its potentially favorable hepatic tolerability profile, may make levoketoconazole a better option for combination therapy.

Preoperative treatment

The goal of presurgical medical treatment is to decrease the comorbidities at the time of surgery and improve postoperative outcomes. Preoperative treatment could thus be of particular interest in patients with comorbidities that are difficult to manage with classical antihypertensive or antidiabetic treatments. Results of preoperative therapy with adrenal steroidogenesis inhibitors have not been conclusive because some patients were only evaluated based upon the rate of normal UFC obtained before surgery and not on the rate of improvement of comorbidities [[61]]. In a retrospective study of 16 patients who received adequate presurgical cortisol suppression therapy with ketoconazole or metyrapone prior to undergoing transsphenoidal surgery, postoperative cortisol suppression was observed and, surprisingly, long-term remission was significantly increased compared with patients with borderline or inadequate cortisol suppression pretreatment [[62]]. However, a retrospective study of previously untreated patients who had a mean baseline UFC level of 793 nmol/24 h (approximately 3 times ULN) and who were treated with steroidogenic inhibitors prior to surgery found that preoperative treatment with ketoconazole and/or metyrapone yielded normal UFC levels in approximately 50 % of patients, but normalization of UFC did not necessarily lead to clinical benefit [[61]]. Further studies with more well-defined patient inclusion criteria will be required to clarify the role of presurgical treatment. Moreover, the duration of this presurgical treatment is also controversial. Taking into account the time needed to recover from comorbidities, for instance after bilateral adrenalectomy, would argue for the need for a prolonged presurgical medical treatment [[63]].

Subclinical adrenal CS

Though controversial, subclinical CS or mild adrenal hypercortisolism is defined as a subtle hypersecretion of cortisol that does not fully manifest in a clinical phenotype [[64]]. However, subclinical CS may be associated with an increased risk of comorbidities, such as hypertension, type 2 diabetes, osteoporosis, dyslipidemia, or coronary heart disease as a result of chronic cortisol elevation, but this association has not been conclusively demonstrated. As a result of the sparse data around treatment of subclinical CS, treatment guidelines for subclinical CS vary [[65]]. Some guidelines recommend adrenalectomy, particularly for patients with worsening comorbidities, while others advocate for careful monitoring of the patient [[6], [66], [67]]. While the optimal treatment for these patients is not clear, steroidogenic inhibitors are not currently recommended for the treatment of subclinical CS. Thus, there is a clear need for more studies evaluating the best course of treatment for these patients. For instance, administering steroidogenesis inhibitors as a first-line treatment might obviate the need for adrenalectomy in patients who have bilateral adrenal disease, have contraindications, or refuse surgery, if their comorbidities are improved with the medical treatment.


CS has higher morbidity and mortality rates if not appropriately treated. Surgery is the first line of treatment, but many patients do not achieve remission or experience disease recurrence following surgery. Adrenal steroidogenesis inhibitors are associated with high rates of cortisol normalization and clinical improvements. Combination therapies of well-studied drugs might allow for lower doses with better tolerability. However, data from CS studies is limited and there is a need for prospective studies of adrenal steroidogenesis inhibitors with long-term follow-up. In addition, agents with improved tolerability and potency are needed. In phase 2 studies, osilodrostat provided cortisol normalization in almost 80 % of patients with no short-term escape. Based on preclinical and early clinical data in patients with diabetes, levoketoconazole may be associated with a number of potential benefits relative to steroidogenesis inhibitors currently in clinical use. Both drugs are currently being evaluated in ongoing phase 3 studies. Treatments that are tailored to each individual patient’s needs are desirable; thus, expanded options for medical treatment could lead to improved overall outcomes for CS patients.


Manuscript editorial support was provided by Erica Chevalier-Larsen, Ph.D. (MedErgy) and was funded by Strongbridge Biopharma. Financial support for Open Access was provided by Strongbridge Biopharma.

Authors contributions

A detailed outline draft manuscript and references were compiled by the authors (MF and FC) and discussed via teleconference. Subsequent manuscript drafts were reviewed by email correspondence. The authors retained full editorial control over manuscript content and approved the final manuscript version.


  1. ST SharmaLK NiemanRA FeeldersCushing’s syndrome: epidemiology and developments in disease managementClin Epidemiol2015728129325945066
  2. OM DekkersE Horvath-PuhoJO JorgensenSC CannegieterV EhrensteinJP VandenbrouckeAM PereiraHT SorensenMultisystem morbidity and mortality in Cushing’s syndrome: a cohort studyJ Clin Endocrinol Metab2013982277228410.1210/jc.2012-358223533241
  3. T ManciniB KolaF ManteroM BoscaroG ArnaldiHigh cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelinesClin Endocrinol (Oxf.)20046176877710.1111/j.1365-2265.2004.02168.x15579193
  4. LK NiemanCushing’s syndrome: update on signs, symptoms and biochemical screeningEur J Endocrinol2015173M33M3810.1530/EJE-15-046426156970
  5. ST SharmaLK NiemanCushing’s syndrome: all variants, detection, and treatmentEndocrinol Metab Clin North Am201140237939110.1016/j.ecl.2011.01.00621565673
  6. LK NiemanBM BillerJW FindlingMH MuradJ Newell-PriceMO SavageA TabarinTreatment of Cushing’s syndrome: an Endocrine Society Clinical Practice GuidelineJ Clin Endocrinol Metab20151002807283110.1210/jc.2015-181826222757
  7. LK NiemanMedical therapy of Cushing’s diseasePituitary20025778210.1023/A:102230842999212675504
  8. C GuerinD TaiebG TregliaT BrueA LacroixF SebagF CastinettiBilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?Endocr Relat Cancer201623R131R14210.1530/ERC-15-054126739832
  9. D Cuevas-RamosM FleseriuTreatment of Cushing’s disease: a mechanistic updateJ Endocrinol2014223R19R3910.1530/JOE-14-030025134660
  10. E DanielJD Newell-PriceTherapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing’s syndromeEur J Endocrinol2015172R263R28010.1530/EJE-14-101425637072
  11. R PivonelloM De LeoA CozzolinoA ColaoThe treatment of Cushing’s diseaseEndocr Rev20153638548610.1210/er.2013-104826067718
  12. US Food and Drug Administration (2013) FDA drug safety communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infractions continues; linked to patient death.
  13. European Medicines Agency (2012) Orphan designation EU/3/12/965.
  14. RA FeeldersLJ HoflandMedical treatment of Cushing’s diseaseJ Clin Endocrinol Metab20139842543810.1210/jc.2012-312623345100
  15. NIZORAL® (2013) (Ketoconazole tablets) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc
  16. D DunmireTB FreedmanLA NafieC AeschlimannJG GerberJ GalDetermination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroismChirality200517SupplS101S10810.1002/chir.2012015772975
  17. Y IdeyamaM KudohK TanimotoY SusakiT NanyaT NakaharaH IshikawaT FujikuraH AkazaH ShikamaYM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cellsJpn J Pharmacol199979221322010.1254/jjp.79.21310202857
  18. DM RotsteinDJ KerteszKA WalkerDC SwinneyStereoisomers of ketoconazole: preparation and biological activityJ Med Chem199235152818282510.1021/jm00093a0151495014
  19. B WellesGlucocorticoids in type 2 diabetes mellitus and the metabolic syndromeDrug Dev Res20066757310.1002/ddr.20124
  20. RE SteenH KapelrudE HaugH FreyIn vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumourActa Endocrinol (Copenh.)19911253313341659100
  21. M FleseriuS PetersennMedical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockersPituitary20151824525210.1007/s11102-014-0627-025560275
  22. RH MortimerGR CannellCM ThewJP GalliganKetoconazole and plasma and urine steroid levels in Cushing’s diseaseClin Exp Pharmacol Physiol19911856356910.1111/j.1440-1681.1991.tb01492.x1655322
  23. F CastinettiL GuignatP GiraudM MullerP KamenickyD DruiP CaronF LucaB DonadilleMC VantyghemH BihanB DelemerG RaverotE MotteM PhilipponI MorangeB Conte-DevolxL QuinquisM MartinieD VezzosiM Le BrasC BaudryS Christin-MaitreB GoichotP ChansonJ YoungO ChabreA TabarinJ BertheratT BrueKetoconazole in Cushing’s disease: is it worth a try?J Clin Endocrinol Metab2014991623163010.1210/jc.2013-362824471573
  24. Ketoconazole HRA 200 mg tablets (2015) Summary of Product Characteristics
  25. M FleseriuS PetersennMedical management of Cushing’s disease: what is the future?Pituitary20121533034110.1007/s11102-012-0397-522674211
  26. V Lo Re 3rdDM CarbonariJD LewisKA FordeDS GoldbergKR ReddyK HaynesJA RoyD ShaAR MarksJL SchneiderBL StormDA CorleyOral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease statusAm J Med201612928329110.1016/j.amjmed.2015.10.02926597673
  27. Metopirone (2010) Metopirone product insert. Novartis Pharmaceuticals
  28. DF RigelF FuM BeilCW HuG LiangAY JengPharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyraponeJ Pharmacol Exp Ther201033423224310.1124/jpet.110.16714820354176
  29. WS Coppage JrD IslandM SmithGW LiddleInhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylationJ Clin Invest1959382101211010.1172/JCI10398813811859
  30. E DanielS AylwinO MustafaS BallA MunirK BoelaertV ChortisDJ CuthbertsonC DaousiSP RajeevJ DavisK CheerW DrakeK GunganahA GrossmanM GurnellAS PowlsonN KaravitakiI HuguetT KearneyK MohitK MeeranN HillA ReesAJ LansdownPJ TrainerAE MinderJ Newell-PriceEffectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patientsJ Clin Endocrinol Metab20151004146415410.1210/jc.2015-261626353009
  31. J HeynC GeigerCL HinskeJ BriegelF WeisMedical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidatePituitary20121511712510.1007/s11102-011-0314-321556813
  32. Hospira Inc. (2011) Amidate (etomidate injection, USP) product description
  33. VA PredaJ SenN KaravitakiAB GrossmanEtomidate in the management of hypercortisolaemia in Cushing’s syndrome: a reviewEur J Endocrinol201216713714310.1530/EJE-12-074622577107
  34. HM SchulteG BenkerD ReinweinWG SippellB AllolioInfusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjectsJ Clin Endocrinol Metab1990701426143010.1210/jcem-70-5-14262159485
  35. LYSODREN® (2016) (mitotane) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb Company
  36. DE SchteingartHS TsaoCI TaylorA McKenzieR VictoriaBA TherrienSustained remission of Cushing’s disease with mitotane and pituitary irradiationAnn Intern Med19809261361910.7326/0003-4819-92-5-6136247946
  37. C BaudryJ CosteRB KhalilS SilveraL GuignatJ GuibourdencheH AbbasP LegmannX BertagnaJ BertheratEfficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single centerEur J Endocrinol201216747348110.1530/EJE-12-035822815335
  38. B DonadilleL GroussinC WaintropH AbbasF TenenbaumM-A DugueJ CosteX BertagnaJ BertheratManagement of Cushing’s syndrome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para’-dichloro-diphenyl-dicholor-ethane: findings in 23 patients from a single centerJ Clin Endocrinol Metab20109553754410.1210/jc.2009-131720061433
  39. S SalenaveV BernardC Do CaoL GuignatA BachelotS LeboulleuxC DroumaguetH Bry-GauillardP PeirreL CriniereP SantulliP TouraineP ChansonM SchlumbergerD MaiterE BaudinJ YoungOvarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing’s diseaseEur J Endocrinol201517214114910.1530/EJE-14-067025411236
  40. DA CalhounWB WhiteH KrumW GuoG BermannA TrapaniMP LefkowitzJ MenardEffects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trialCirculation20111241945195510.1161/CIRCULATIONAHA.111.02989221986283
  41. M FleseriuR PivonelloJ YoungAH HamrahianME MolitchC ShimizuT TanakaA ShimatsuT WhiteA HilliardC TianN SauterBM BillerX BertagnaOsilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s diseasePituitary20161913814810.1007/s11102-015-0692-z26542280
  42. X BertagnaR PivonelloM FleseriuY ZhangP RobinsonA TaylorCE WatsonM MaldonadoAH HamrahianM BoscaroBM BillerLCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept studyJ Clin Endocrinol Metab2014991375138310.1210/jc.2013-211724423285
  43. Shimatsu A, Sauter N, Kelly RY, Unge P, Zhi X, Fleseriu M (2015) Study design of a phase III, multicenter, double-blind, randomized withdrawal study following a 24-week, single-arm, open-label osilodrostat (LCI699) treatment to evaluate the long-term safety and efficacy of osilodrostat in patients with Cushing’s disease (CD). In: Pituitary tumors—non-acromegaly (posters), pp SAT-506-SAT-506. doi:10.1210/endo-meetings.2015.NP.17.SAT-506
  44. Salvatori R, DelConte A, Geer EB, Koziol T, Jorkasky D (2015) An open-label study to assess the safety and efficacy of levoketoconazole (COR-003) in the treatment of endogenous Cushing’s syndrome. In: Adrenal tumors, glucocorticoid regulation and action (posters), pp FRI-376-FRI-376. doi:10.1210/endo-meetings.2015.AHPAA.5.FRI-376
  45. Thieroff-Ekerdt R, Lavin P, Abou-Gharbia M, France N (2016) Pharmacology of COR-003 (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome. In: Pituitary disorders—it’s not the anterior pituitary (posters), pp SAT-547-SAT-547. doi:10.1210/endo-meetings.2016.NP.15.SAT-547
  46. N ZenkerDE BernsteinThe estimation of small amounts of corticosterone in rat plasmaJ Biol Chem195823169570113539004
  47. SL SchwartzM RendellAJ AhmannA ThomasCJ Arauz-PachecoBR WellesSafety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitusClin Ther20083061081108810.1016/j.clinthera.2008.05.02118640464
  48. R ArakakiB WellesKetoconazole enantiomer for the treatment of diabetes mellitusExpert Opin Investig Drugs201019218519410.1517/1354378090338141120047506
  49. A RizkJ HoneggerM MilianT PsarasTreatment options in Cushing’s diseaseClin Med Insights Oncol20126758422346367
  50. N SoninoThe use of ketoconazole as an inhibitor of steroid productionN Engl J Med198731781281810.1056/NEJM1987092431713073306384
  51. NP van ErpHJ GuchelaarBA PloegerJA RomijnJ HartighH GelderblomMitotane has a strong and a durable inducing effect on CYP3A4 activityEur J Endocrinol201116462162610.1530/EJE-10-095621220434
  52. R DumaineML RoyAM BrownBlockade of HERG and Kv1.5 by ketoconazoleJ Pharmacol Exp Ther19982867277359694927
  53. MJ BoyceKJ BaisleySJ WarringtonPharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover studyBr J Clin Pharmacol20127341142110.1111/j.1365-2125.2011.04093.x21883386
  54. B DarpoG FerberM ZhouM SumerayP SagerLomitapide at supratherapeutic plasma levels does not prolong the Qtc interval–results from a TQT study with moxifloxacin and ketoconazoleAnn Noninvasive Electrocardiol20131857758910.1111/anec.1210324118671
  55. M FleseriuME MolitchC GrossDE SchteingartT VaughanBM BillerA new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with miferpistoneEndocr Pract20131931332610.4158/EP12149.RA23337135
  56. M BarbotN AlbigerF CeccatoM ZilioAC FrigoL DenaroF ManteroC ScaroniCombination therapy for Cushing’s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?Pituitary.20141710911710.1007/s11102-013-0475-323468128
  57. RA FeeldersC de BruinAM PereiraJA RomijnRT Netea-MaierAR HermusPM ZelissenR van HeerebeekFH de JongAJ van der LelyWW de HerderLJ HoflandSW LambertsPasireotide alone or with cabergoline and ketoconazole in Cushing’s diseaseN Engl J Med20103621846184810.1056/NEJMc100009420463350
  58. JB CorcuffJ YoungP Masquefa-GiraudP ChansonE BaudinA TabarinRapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazoleEur J Endocrinol201517247348110.1530/EJE-14-091325624013
  59. P KamenickyC DroumaguetS SalenaveA BlanchardC JublancJF GautierS Brailly-TabardS LeboulleuxM SchlumbergerE BaudinP ChansonJ YoungMitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndromeJ Clin Endocrinol Metab2011962796280410.1210/jc.2011-053621752886
  60. L LiK VashishtJ BoisclairW LiT-H LinHA SchmidW KluweH SchoenfeldP HoffmannOsilodrostat (LCI699), a potent 11-beta-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: a 13-week study in ratsToxicol Appl Pharmacol201528622423310.1016/j.taap.2015.05.00425981165
  61. E ValassiI CrespoI GichJ RodriguezSM WebbA reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndromeClin Endocrinol (Oxf.)20127773574210.1111/j.1365-2265.2012.04424.x22533782
  62. OF van den BoschAM StadesPM ZelissenIncreased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing’s diseaseClin Endocrinol (Oxf.)20148018419010.1111/cen.1228623841642
  63. RS SippelDM ElarajE KebebewS LindsayJB TyrrellQY DuhWaiting for change: symptom resolution after adrenalectomy for Cushing’s syndromeSurgery20081441054106010.1016/j.surg.2008.08.02419041018
  64. GN ZografosI PerysinakisE VassilatouSubclinical Cushing’s syndrome: current concepts and trendsHormones20141332333710.14310/horm.2002.150625079456
  65. J ShenM SunB ZhouJ YanNonconformity in the clinical practice guidelines for subclinical Cushing’s syndrome: which guidelines are trustworthy?Eur J Endocrinol201417142143110.1530/EJE-14-034524986532
  66. MM GrambachBM BillerGD BraunsteinKK CampbellJA CarneyPA GodleyEL HarrisJKT LeeYC OertelMC PosnerJA SchlechteHS WieandManagement of the clinically inapparent adrenal mass (“incidentaloma”)Ann Intern Med200313842442910.7326/0003-4819-138-5-200303040-0001312614096
  67. M TerzoloA StiglianoI ChiodiniP LoliL FurlaniG ArnaldiG ReimondoA PiaV ToscanoM ZiniG BorrettaE PapiniP GarofaloB AllolioB DupasF ManteroA TabarinAME position statement on adrenal incidentalomaEur J Endocrinol201116485187010.1530/EJE-10-114721471169
  68. Novartis (2016) Metopirone (metyrapone, USP) prescribing information
  69. M De MartinPM TojaK GouleneP RadaeliiF CavagniniM Stramba-BadialeP GiraldiNo untoward effect of long-term ketoconazole administration on electrocardiographic QT interval in patients with Cushing’s diseaseBasic Clin Pharmacol Toxicol201618827928310.1111/bcpt.12490
  70. HW DaniellOpioid contribution to decreased cortisol levels in critical care patientsArch Surg20081431147114810.1001/archsurg.143.12.114719075164
  71. M VinclairC BrouxP FaureJ BrunC GentyC JacquotO ChabreJF PayenDuration of adrenal inhibition following a single dose of etomidate in critically ill patientsIntensive Car Med20083471471910.1007/s00134-007-0970-y
  72. CA MooreSF HamiltonAL UnderhillPotentiation of etomidate anesthesia by verapermil: a report of two casesHosp Pharm1989242425
  73. H DaniellOpioid and benzodiazepine contributions to etomidate-associated adrenal insufficiencyIntensive Care Med2016342117211810.1007/s00134-008-1264-8
  74. Ting L, Tripahti AP, Darstein C, White T, Sauter N (2015) Effects of osilodrostat (LCI699) on cytochrome P450 enzymes in healthy volunteers indicates a low drug-drug interactions potential. Endocrine Abstracts 37, GP.22.05
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as hyperaldosteronism.